Page 8 - Eachf News Today

Message : Required fields Financial results for the full year 2020 -- Highlights -- Surge in orders; order entry increased to CHF 855.2 million (2019: CHF 638.6 million) -- Full-year growth of 38.5% in local currencies or 33.9% in Swiss francs -- Growth trend further accelerated in the second half of the year -- Sales of CHF 730.9 million (2019: CHF 636.8 million) -- Full-year growth of 18.7% in local currencies and 14.8% in Swiss...

24 February 2021 | 09:58am StockMarketWire.com - Chesterfield Resources reported high grade drill results from its its copper, gold, zinc and silver exploration project in Cyprus. The company encountered high grades across four revenue metals and on two discrete targets, ... [and] the native copper intercepts are also indicative of a nearby deposit, the company said. The next objective was to locate nearby larger deposits of similar grade material to delineate a commercial discovery, it added. ...

In a research note published by Amit Goel, Barclays advises its customers to Sell the stock. The target price has been modified and is now set at CHF 13.70 compared to CHF 13.40. | February 27, 2021

Barclayss analyst Amit Goel has upgraded his rating from Neutral to Buy. The target price is reviewed upwards from CHF 12.50 to CHF 14. | February 27, 2021

Deutsche Bank confirms his opinion on the stock and remains Neutral. The target price is lowered from CHF 120 to CHF 115. | February 23, 2021

EQS-News: FiCAS AG reaches two further milestones: CHF 10 Mio. AuM; YTD Performance over 100% vom 19.02.2021, 17:50 Uhr Bild: pixabay.com FiCAS AG reaches two further milestones: CHF 10 Mio. AuM; YTD Performance over 100% 19.02.2021 / 17:50 CHF 10 Mio. AuM; YTD Performance over 100% Today FiCAS AG has passed the cap of CHF 10 million AuM. The 15 FiCAS Active Crypto ETP (ISIN CH0548689600) records a performance in excess of 100% year-to-date. Zug, Switzerland - 19 February 2021 - FiCAS AG has...

email article Sacubitril/valsartan (Entresto) became the first drug to get a broad heart failure indication that reaches into the normal ejection fraction range for prevention of cardiovascular death and hospitalization, Novartis announced. FDA granted the drug an expanded indication "to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fra...

Sales from continuing operations decreased by 5 % in local currency to CHF 3.860 billion EBITDA margin preserved at 15.0 % in a challenging environment... | February 14, 2021

Analyst Keyur Parekh from Goldman Sachs research considers the stock attractive and recommends it with a Buy rating. The target price has been modified and is now set at CHF 106 compared to CHF 109. | February 6, 2021

United states. >> they believed they would be protected. >> absolutely. >> -- and honored. >> yes. and we just threw them under the bus in 24 hours. it is appalling. and its disgraceful. and then today when the turks quite predictably are bombing the jesus out of syria, and trump allegedly orders the u.s. military not to come to their defense, not to protect them. weve crossed a rubicon here of betrayal that i think is going to haunt us for decades to come. >> the end of when south vietnam final...